Biochemical studies of cancer patients treated with acridine derivative (C-283). IV. Changes in the levels of serum haptoglobin and sialic acid.
D000166:Acridines / Q000008:administration & dosage / Q000627:therapeutic use*; D000230:Adenocarcinoma / Q000188:drug therapy; D000231:Adenocarcinoma, Papillary / Q000188:drug therapy; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001201:Ascites / Q000150:complications; D001202:Ascitic Fluid / Q000032:analysis; D002277:Carcinoma / Q000188:drug therapy; D003536:Cystadenocarcinoma / Q000188:drug therapy; D003537:Cystadenoma / Q000188:drug therapy; D004123:Dimethylamines / Q000008:administration & dosage / Q000627:therapeutic use; D004407:Dysgerminoma / Q000188:drug therapy; D005260:Female; D006242:Haptoglobins / Q000032:analysis*; D006801:Humans; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D009438:Neuraminic Acids / Q000097:blood*; D009574:Nitro Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000150:complications / Q000188:drug therapy*; D012075:Remission, Spontaneous; D013724:Teratoma / Q000188:drug therapy
D000166:Acridines; D000970:Antineoplastic Agents; D004123:Dimethylamines; D006242:Haptoglobins; D009438:Neuraminic Acids; D009574:Nitro Compounds